Allarity Therapeutics announced significant corporate actions following its 2024 Annual Meeting on September 3. The company will execute a 1-for-30 reverse stock split effective September 11, 2024, at 12:01 a.m. ET. The split will automatically combine every 30 shares into one share, with fractional shares rounded up to the next whole number. The stock will continue trading under symbol "ALLR" on Nasdaq.The company also approved reducing its authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, stockholders approved expanding the 2021 Equity Incentive Plan share reserve from 2.17 million to 10.59 million shares.Other approved measures include the election of two Class II directors through 2027, ratification of Wolf & Company as auditor for 2024, and an amendment limiting certain officer liabilities under Delaware law. All seven proposals received sufficient stockholder approval at the annual meeting.

Allarity Therapeutics announced significant corporate actions following its 2024 Annual Meeting on September 3. The company will execute a 1-for-30 reverse stock split effective September 11, 2024, at 12:01 a.m. ET. The split will automatically combine every 30 shares into one share, with fractional shares rounded up to the next whole number. The stock will continue trading under symbol "ALLR" on Nasdaq.The company also approved reducing its authorized shares from 750.5 million to 250.5 million, with common stock authorization decreasing from 750 million to 250 million shares. Additionally, stockholders approved expanding the 2021 Equity Incentive Plan share reserve from 2.17 million to 10.59 million shares.Other approved measures include the election of two Class II directors through 2027, ratification of Wolf & Company as auditor for 2024, and an amendment limiting certain officer liabilities under Delaware law. All seven proposals received sufficient stockholder approval at the annual meeting.